HOME | COUNTRIES | CITIES | COMPANIES | SPORTS | CARS
news videos images websites wiki
 

Gilead Sciences NEWS

Is there Inherent Value in Gilead Sciences, Inc. (NASDAQ:GILD) Shares? Analyst's Take  -  Engelwood Daily
Sell-side Street analysts covering Gilead Sciences, Inc. (NASDAQ:GILD) presently have an average rating of 1.95 on company shares. This consensus rating is using 14 analysts polled by Zacks Research. On a numerical scale from 1 to 5, a rating of 1 or 2 ...

Gilead Sciences Inc. (GILD) Stake Reduced by North Point Portfolio Managers Corp OH  -  The Cerbat Gem
Gilead Sciences logo North Point Portfolio Managers Corp OH decreased its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned ...

Bartlett & Co. LLC Has $27942000 Stake in Gilead Sciences Inc. (GILD)  -  The Cerbat Gem
Gilead Sciences logo Bartlett & Co. LLC boosted its position in Gilead Sciences Inc. (NASDAQ:GILD) by 1.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 334,952 ...
Calamos Advisors LLC Raises Stake in Gilead Sciences Inc. (GILD)  -  BBNS
Gilead Sciences logo Calamos Advisors LLC raised its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 32.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 723,334 shares ...
Underhill Investment Management LLC Purchases 17850 Shares of Gilead Sciences Inc. (GILD)  -  BBNS
Gilead Sciences logo Underhill Investment Management LLC boosted its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 15.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 130,750 shares of the ...

Gilead Sciences, Inc. (GILD) Options Traders Eye an End-of-Week Rebound  -  Schaeffers Research (blog)
Gilead Sciences, Inc. (NASDAQ:GILD) is fresh off a more than two-year low of $73.90, and was last seen sitting on a 2% loss at $73.93. Amid these technical woes, the drugmaker's options volume is slightly accelerated, running at 1.3 times the usual ...

Allergan Challenges Intercept With Tobira NASH Drug  -  Investor's Business Daily
Allergan (AGN) is taking on Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT) with its acquisition of Tobira Therapeutics (TBRA), but Mizuho analyst Irina Koffler likes the deal, saying a key Tobira drug has "a solid chance of approval ...
Turning Bullish On Gilead - Bezek's Daily Briefing  -  Seeking Alpha
With the stock at $120, just a couple bucks short of its all-time high, I called "sell" on Gilead in a contest-winning article that generated more than 300 comments, mostly negative. That's no surprise, in it, I specifically warned that many people ...
Stocks in News: Ocular Therapeutix, Inc. (NASDAQ:OCUL), Gilead Sciences Inc. (NASDAQ:GILD), Chubb Limited ...  -  Benchmark Monitor
On 10 October Ocular Therapeutix, Inc. (NASDAQ:OCUL) traded 415385 shares as and was closed at $6.81. Company is -60.73% away from its one year high and is moving 68.56% ahead of its one year low. Stock monthly performance is recorded as 0.44% ...
Pro ad report: All the data on journal spending in 1H 2016  -  Medical Marketing and Media
Professional advertising spending behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. But cancer drugs once again were the hottest category. Check out ...
 

Gilead Sciences Videos

Gilead Sciences - Hot or Not
05:32:39
Gilead Sciences - Hot or Not
What's Gilead Sciences Doing With All That Cash?
17:39:09
What's Gilead Sciences Doing With All That Cash?
Gilead Sciences
17:59:12
Gilead Sciences
Gilead Sciences Outlook For 2016: What You Need To Know
13:22:18
Gilead Sciences Outlook For 2016: What You Need To Know
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
18:41:42
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
The Next Big Thing In Biotech: Gilead Sciences
11:02:14
The Next Big Thing In Biotech: Gilead Sciences
What's Behind Gilead Sciences Drop In Hepatitis C Sales?
17:39:09
What's Behind Gilead Sciences Drop In Hepatitis C Sales?
Gilead Sciences Doesn’t Have Many Fans on Wall Street: Jim Cramer
18:41:30
Gilead Sciences Doesn’t Have Many Fans on Wall Street: Jim Cramer
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994
14:21:11
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994
Gilead Sciences: A Bargain Worth Stuffing in Investor Stockings
16:48:07
Gilead Sciences: A Bargain Worth Stuffing in Investor Stockings
 

Gilead Sciences Images

www.dall.co.uk
Gilead Sciences - Dall Cleaning Services
940 x 450 jpeg 56kB
breakingfinancenews.com
Gilead Sciences Still Poised For Growth
796 x 496 jpeg 57kB
betablog.org
Photo: Gilead Sciences
500 x 497 jpeg 150kB
www.infohep.org
Image: Gilead Sciences
1000 x 600 jpeg 138kB
www.forbes.com
How Gilead Sciences Can Deliver A Double: Part Two
640 x 427 jpeg 52kB
www.forbes.com
Gilead Sciences Moves Up In Market Cap Rank, Passing PepsiCo
600 x 340 png 19kB
www.forbes.com
Gilead Sciences, Lockheed Martin And 5 Other Winning Stocks Set For A ...
620 x 434 png 200kB
www.bloomberg.com
... study jb reed bloomberg gilead sciences inc s truvada aids medication
333 x 500 jpeg 71kB
www.techtimes.com
FDA Approves Gilead Drug That Can Treat All Forms Of Hepatitis C Virus ...
869 x 600 jpeg 67kB
www.slideshare.net
... Gilead Sciences, Inc. Founder & CEO, re Combating AIDS Virus Feb 1996
638 x 826 jpeg 58kB
www.nydailynews.com
Truvada shows 44% reduction in HIV infection rate amongst men: study ...
970 x 728 jpeg 39kB
www.bidnessetc.com
Merck & Co., Inc. (MRK) HCV Treatment: The Next Big Breakthrough?
960 x 540 jpeg 49kB
angelamcmillan.com
Atripla Tablets
308 x 379 jpeg 13kB
www.nydailynews.com
The Food and Drug Administration okayed Truvada, calling little blue ...
635 x 944 jpeg 66kB
esofosbuvir.com
Sofosbuvir FDA approval - Hepatitis C Society
470 x 320 jpeg 70kB
www.medscape.com
Antiviral Sensitizes HPV Cervical Cancer to Chemoradiation
800 x 600 jpeg 70kB
esofosbuvir.com
Harvoni Cost in USA, Canada, Europe, Egypt, India and More - Sovaldi ...
1280 x 720 jpeg 144kB
factsreporter.com
Price Target Analysis of Select Medical Holdings Corporation (NYSE:SEM ...
384 x 253 jpeg 17kB
www.bidnessetc.com
Bristol-Myers Squibb Co To Join HCV Drug Race Soon; Daklinza sNDAs Win ...
960 x 540 jpeg 45kB
hdimagelib.com
Science Logos Symbols Atom Molecule Science Symbol
450 x 437 jpeg 40kB
 

Gilead Sciences WebSites

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the ...
View the basic GILD stock chart on Yahoo Finance. Change the date range, chart type and compare Gilead Sciences, Inc. against other companies.
Gilead Sciences Inc. Stock - GILD news, historical stock charts, analyst ratings, financials, and today’s Gilead Sciences Inc. stock price.
As part of a rapidly growing science-driven organization, colleagues at Gilead are revolutionizing healthcare by bringing urgently needed medicines to patients in the ...
News about Gilead Sciences, Inc. Commentary and archival information about Gilead Sciences, Inc. from The New York Times.
Gilead Sciences, Inc. is actively advancing pharmaceuticals to address unmet medical needs for patients living with life-threatening diseases globally.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients ...
Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of ...
Gilead Sciences Inc, GILD real time stock quotes, news, videos at CNBC.com
 

Gilead Sciences Wiki

Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. In 2006, Gilead acquired two companies which were developing drugs to treat patients with pulmonary diseases.The company's current commercially available products include Atripla, Complera, Emtriva, Viread, Tybost, Vitekta, Truvada, Stribild, Harvoni, Hepsera, Sovaldi, Zydelig, Letairis, Lexiscan, Ranexa, Cayston, Tamiflu, AmBisome, and Macugen.Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2015, the company had approximately 7,900 full-time employees. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.The company's name and logo refer to the Balm of Gilead, inspired by a 1965 play by Lanford Wilson featuring the underworld adventures of the patrons of the namesake cafe.